Skip to content

Evaluation of the clinical effect of Tiaozangyangfei decoction on stable phase of chronic obstructive pulmonary disease with deficiency of both lung and kidney by FRAX and bone metabolic biochemical indexes

Evaluation of the clinical effect of Tiaozangyangfei decoction on stable phase of chronic obstructive pulmonary disease with deficiency of both lung and kidney by FRAX and bone metabolic biochemical indexes

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003872
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) meet the criteria of TCM Syndrome diagnosis for stable COPD; (2) aged 40 to 80 years old; (3) patient denied participating in clinical trial of other drugs within 1 month; (4) patient volunteered to take the trial and signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) patients with acute exacerbation of chronic obstructive pulmonary disease; (2) patients with chronic wheezing and chronic cough caused by asthma, lung and bronchial tumors, Tuberculosis, bronchiectasis and allergens; (3) women in pregnancy and lactation with severe heart and lung diseases; (4) with primary diseases of the serious circulatory system, urinary system, digestive system, blood system, endocrine and rheumatic immune system, include patients with cancer or AIDS; (5) the definition of persons with disabilities as set out in the relevant legal articles, including blindness, deafness, muteness, mental retardation, Mental Retardation, etc.; (6) alcohol and certain drugs are suspected of having been abused in patients; Or other medical history that significantly reduces the likelihood of admission or complicates the whole process of admission, such as frequent changes of place of work or residence, which may result in loss of follow-up; (7) patients undergoing clinical trials of other drugs in the last month.

Design outcomes

Primary

MeasureTime frame
Pulmonary function;

Countries

China

Contacts

Public ContactYada Zhang

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

976825186@qq.com+86 18817775947

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026